Oracle, Moderna, Goldman Sachs Option Activity Surges on Friday
PorAinvest
viernes, 12 de septiembre de 2025, 1:57 pm ET1 min de lectura
GS--
Oracle Corp reported a significant increase in option activity, with 904,524 contracts traded, indicating substantial interest from investors. This activity was driven by the company's robust financial performance, as highlighted in its Form 10-Q report for the third quarter. Total revenues increased by 12%, with cloud and software revenues contributing to 86% of the total revenue growth [1].
Moderna Inc experienced a notable drop in its stock price following a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report came as Health and Human Services Secretary Robert F. Kennedy Jr. moves to change vaccine policy in the U.S. [2]. Despite the report, Moderna maintains that the safety of its vaccine is rigorously monitored by the company, the FDA, and regulators in more than 90 countries [2].
Goldman Sachs Group Inc saw 20,565 contracts traded, representing 2.1 million underlying shares. The company reported a quarterly EPS of $10.91, exceeding analyst estimates, and experienced a 14.5% increase in revenue year-over-year. Institutional investors and hedge funds own 71.21% of the company's stock [3].
The increased option activity in these companies reflects investor interest in their respective financial performances and strategic developments. Investors should closely monitor these companies' future earnings and market developments to make informed investment decisions.
MRNA--
ORCL--
Notable Friday option activity was seen in Oracle Corp (ORCL), Moderna Inc (MRNA), and Goldman Sachs Group Inc (GS). ORCL saw 904,524 contracts traded, representing 90.5 million underlying shares. MRNA saw 242,485 contracts traded, representing 24.2 million underlying shares. GS saw 20,565 contracts traded, representing 2.1 million underlying shares.
Notable Friday option activity was observed in Oracle Corp (ORCL), Moderna Inc (MRNA), and Goldman Sachs Group Inc (GS). ORCL saw 904,524 contracts traded, representing 90.5 million underlying shares. MRNA saw 242,485 contracts traded, representing 24.2 million underlying shares. GS saw 20,565 contracts traded, representing 2.1 million underlying shares.Oracle Corp reported a significant increase in option activity, with 904,524 contracts traded, indicating substantial interest from investors. This activity was driven by the company's robust financial performance, as highlighted in its Form 10-Q report for the third quarter. Total revenues increased by 12%, with cloud and software revenues contributing to 86% of the total revenue growth [1].
Moderna Inc experienced a notable drop in its stock price following a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report came as Health and Human Services Secretary Robert F. Kennedy Jr. moves to change vaccine policy in the U.S. [2]. Despite the report, Moderna maintains that the safety of its vaccine is rigorously monitored by the company, the FDA, and regulators in more than 90 countries [2].
Goldman Sachs Group Inc saw 20,565 contracts traded, representing 2.1 million underlying shares. The company reported a quarterly EPS of $10.91, exceeding analyst estimates, and experienced a 14.5% increase in revenue year-over-year. Institutional investors and hedge funds own 71.21% of the company's stock [3].
The increased option activity in these companies reflects investor interest in their respective financial performances and strategic developments. Investors should closely monitor these companies' future earnings and market developments to make informed investment decisions.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios